Biogen Inc BIIB:NASDAQ (Common Stock)

LastDaily Change / % ChangeDividend YieldVolumeAvg Volume (10 day)
282.96 -1.74   -0.61%--3,110,0191.4M
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 7/25/2017

Latest News Headlines for Biogen Inc

Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance

We supplement our consolidated financial statements presented on a GAAP basis by providing additional measures which may be considered "Non-GAAP" financial measures under applicable SEC rules. We believe that the disclosure of these Non-GAAP financial measures provides additional insight into the ongoing economics of our business and reflects how we manage our business internally, set operational goals and forms the basis of our management incentive programs. These Non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be viewed in isolation or as a substitute for reported, or GAAP, net income attributable to Biogen Inc. and diluted earnings per share.

( BIIB ) Investor Network: Biogen Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / July 25, 2017 / Biogen Inc. (NASDAQ: BIIB) will be discussing their earnings results in their Q2 Earnings Call to be held on Tuesday, July 25, 2017 at 8:00 AM Eastern Time.

Alisha A. Alaimo Appointed SVP of Biogen's US Therapeutic Operations

CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 24, 2017-- Biogen (NASDAQ: BIIB) announced today the appointment of Alisha A. Alaimo to Senior Vice President of US Therapeutic Operations, where she will lead sales and marketing, market access, patient services and commercial operations and strategy.

View more recent headlines

Peers Information HelpBIIB Biogen Inc vs. Peers

Biogen Inc
Shire PLC (ADR)
Allergan plc
Mylan NV
Novo Nordisk A/S (ADR)
Biogen Inc
Shire PLC (ADR)
Allergan plc
Mylan NV
Novo Nordisk A/S (ADR)
Biogen Inc
Shire PLC (ADR)
Allergan plc
Mylan NV
Novo Nordisk A/S (ADR)
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings

This report contains detailed information about the company's business finances and management.


Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.


collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open290.01
Previous Close282.96
Day High291.91
Day Low280.24
52 Week High8/2/2016 | 307.325
52 Week Low5/31/2017 | 244.28
% Off 52 Week High(7.93)%
% Off 52 Week Low15.83%
Beta (5 Yr)0.8
Volatility Avg7/25/2017 | 26.06
10-Day Avg. Volume1,368,731
Market data is delayed by at least 15 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)6/30/2017 | 15.23
P/E Ratio6/30/2017 | 18.6
Market CapLarge Cap | 60.02B
Shares Outstanding212.12M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short3.20M
Short Ratio2.9
Short % of Float1.51%
As of 7/15/2017
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.